Date Mailed: July 14, 1999

Sheet 1 of 1

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.28US04	Application Number: 09/020,746
	Applicant: Avi J. Ashkenazi et al.	
	Filing Date: February 9, 1998	Group Art Unit: 1646

#11

MOVE TO REFERENCES ↓ OTHER

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CW	08/883,036	Filed 26 Jun 1997	PCT/US98/02239	X	X	
↓	08/829,536	Filed 28 Mar 1997	PCT/US98/02239	X	X	
↓	08/815,255	Filed 12 Mar 1997	PCT/US98/02239	X	X	

DO NOT PRINT

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
CW	WO 98/41629	24 Sept 1998	PCT	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED 9/23/99

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Date Mailed: December 4, 1998

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.28US04	Application Number: 09/020,746
	Applicant: Ashkenazi et al.	
	Filing Date: February 9, 1998	Group Art Unit: ~~1642~~ 1646

#7

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
Cu	EP 0 510 691 A	October 1992	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED 9/23/99

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Date Mailed: November ____, 1998

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.28US04	Application Number: 09/020,746
	Applicant: Avi J. Ashkenazi et al.	
	Filing Date: February 9, 1998	Group Art Unit: ~~1642~~ 1646

#6

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED
NOV 1 ... 1998
Gr...

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
[illegible]	WO 98/35986	20 Aug 1998	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER [signature]	DATE CONSIDERED 9/23/99

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

FILE COPY

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

#4

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
AM	* 1	3,691,016	12.09.72	Patel, R.			
	* 2	3,969,287	13.07.76	Jaworek et al.			
	* 3	4,179,337	18.12.79	Davis et al.			
	* 4	4,195,128	25.03.80	Hildebrand et al.			
	* 5	4,229,537	21.10.80	Hodgins et al.			
	* 6	4,247,642	27.01.81	Hirohara et al.			
	* 7	4,301,144	17.11.81	Iwashita et al.			
	* 8	4,330,440	18.05.82	Ayers et al.			
	* 9	4,342,566	03.08.82	Theofilopoulos et al.			
	* 10	4,399,216	16.08.83	Axel et al.			
	* 11	4,419,446	06.12.83	Howley et al.			
	* 12	4,496,689	29.01.85	Mitra, G.			
	* 13	4,601,978	22.07.86	Karin, M.			
	* 14	4,640,835	03.02.87	Shimizu et al.			
	* 15	4,670,417	02.06.87	Iwasaki et al.			
	* 16	4,676,980	30.06.87	Segal et al.			
	* 17	4,736,866	12.04.88	Leder et al.			
	* 18	4,791,192	13.12.88	Nakagawa et al.			
	* 19	4,816,567	28.03.89	Cabilly et al.			
	* 20	4,870,009	26.09.89	Evans et al.			
	* 21	4,965,199	23.10.90	Capon et al.			
	* 22	5,010,182	23.04.91	Brake et al.			
	* 23	5,364,934	15.11.94	Drayna et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
AM	* 24	036,776	30.09.81	EPO				
	* 25	073,657	09.03.83	EPO				
	* 26	117,058	29.08.84	EPO				
	* 27	117,060	29.08.84	EPO				
	* 28	125,023 A1	14.11.84	EPO				
	* 29	173,494	05.03.86	EPO				
	* 30	278,776	17.08.88	EPO				
	* 31	307,247	15.03.89	EPO				
	* 32	321,196	21.06.89	EPO				
CM	* 33	362,179	04.04.90	EPO				

Examiner: Clair M. Kaplan

Date Considered: 9/23/98

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
ar	* 34	417,563	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
	* 35	266,710	12.04.89	GERMANY (ENGLISH ABSTRACT ONLY)				
	* 36	WO 87/05330	11.09.87	PCT				
	* 37	WO 89/02922	06.04.89	PCT				
	* 38	WO 89/05859	29.06.89	PCT				
	* 39	WO 90/13646	15.11.90	PCT				
	* 40	WO 91/00358	10.01.91	PCT				
	* 41	WO 91/00360	10.01.91	PCT				
	* 42	WO 91/08291	13.06.91	PCT				
	* 43	WO 92/20373	26.11.92	PCT				
	* 44	WO 93/08829	13.05.93	PCT				
	* 45	WO 94/04679	03.03.94	PCT				
	* 46	WO 94/04690	03.03.94	PCT				
	* 47	WO 94/29348	22.12.94	PCT				
	* 48	WO 95/10540	20.04.95	PCT				
	* 49	WO 95/11301	27.04.95	PCT				
	* 50	WO 95/31544	23.11.95	PCT				
	51	WO 97/01633	16.01.97	PCT				
	52	WO 97/25428	17.07.97	PCT				
ar	* 53	2,211,504	05.07.89	UNITED KINGDOM				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ar	* 54	Tissue Culture, Kruse and Patterson, eds., New York:Academic Press (1973)
	* 55	Chemotherapy Service Ed., M.C. Perry, Baltimore, MD:Williams & Wilkins (1992)
ar	* 56	Mammalian Cell Biotechnology: A Practical Approach, M. Butler, ed., IRL Press (1991)
ar	* 57	Remington's Pharmaceutical Sciences, Oslo et al., eds., 16th edition, Mack Publishing Co. (1980)
	* 58	Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium, Dicke et al., University of Texas M.D. Anderson Hospital (1987)
ar	59	"BLAST Results A-1 - A-47" (GenBank) Do NOT PRINT
	60	"BLAST Results B-1 - B-31" (GenBank, -EST) Do NOT PRINT
ar	61	"BLAST Results C-1 - C-36" (Patent) Do NOT PRINT

Examiner	Date Considered
Clare M. Kelly	9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cm	62	"BLAST Results D-1 - D-40" (Dayhoff -patent) Do NOT PRINT
	63	"BLAST Results E-1 - E-25" (Human -pat) Do NOT PRINT
	64	"BLAST Results F-1 - F-52" (Dayhoff) Do NOT PRINT
	* 65	Adams et al., "Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for μ, α, γ1, γ2a, and γ3 chains" Biochemistry 19:2711-2719 (1980)
	* 66	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of Developing T Cells" Cold Spring Harbor Laboratory Symposium on Programmed Cell Death (Abstr. No. 10) (1995)
	* 67	Aplin et al., "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" CRC Crit. Rev. Biochem. 10(4):259-305 (1981)
	* 68	Ashkenazi and Chamow, "Immunoadhesins: An Alternative to Human Monoclonal Antibodies" Methods: A Companion to Methods in Enzymology 8:104-115 (1995)
	* 69	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" Proc. Natl. Acad. Sci. 88:10535-10539 (1991)
	* 70	Baldwin, "The NF-κB and IκB Proteins: New Discoveries and Insights" Ann. Rev. Immunol. 14:649-681 (1996)
	* 71	Banerji et al., "A Lymphocyte-specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes" Cell 33:729-740 (July 1983)
	* 72	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation" Cell 73:431-445 (1993)
	* 73	Barr et al., "Apoptosis and Its Role in Human Disease" Bio/Technology 12:487-493 (1994)
	* 74	Bianchi et al., "Transformation of the yeast Kluyveromyces lactis by New Vectors Derived from the 1.6 μm Circular Plasmid pKD1" Curr. Genet. 12:185-192 (1987)
	* 75	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" Immunity 6:79-88 (1997)
	* 76	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" The Journal of Immunology 147(1):86-95 (1991)
	* 77	Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" Cell 85:803-815 (1996)
	* 78	Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" Journal of Biological Chemistry 270:387-391 (1995)
	* 79	Boulianne et al., "Production of functional chimaeric mouse/human antibody" Nature 312:643-646 (December 13, 1984)
	* 80	Bradley,, "Production and Analysis of Chimaeric Mice" Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)
cm	* 81	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" Proc. Natl. Acad. Sci. USA 87:3127-3131 (1990)

Examiner	Date Considered
Clair McKelvey	9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cw	* 82	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" Monoclonal Antibody Production Techniques and Applications, New York:Marcel Dekker, Inc. pps. 51-63 (1987)
	* 83	Brojatsch-et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" Cell 87:845-855 (Nov 29, 1996)
	* 84	Bruggemann et al., "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals" Year in Immunology 7:33-40 (1993)
	* 85	Byrn et al., "Biological Properties of a CD4 Immunoadhesin" Nature 344:667-670 (APRIL 12, 1990)
	* 86	Canaani et al., "Regulated Expression of Human Interferon β_1 Gene After Transduction into Cultured Mouse and Rabbit Cells" Proc. Natl. Acad. Sci. USA 79:5166-5170 (September 1982)
	* 87	Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy" Nature 337:525-531 (February 9, 1989)
	88	Caron et al., "Engineered humanized dimeric forms of IgG are more effective antibodies" Journal of Experimental Medicine 176(4):1191-1195 (Oct. 1, 1992)
	* 89	Carter et al., "Humanization of an anti-p185^{HER2} antibody for human cancer therapy" Proc. Natl. Acad. Sci. 89:4285-4289 (1992)
cw	* 90	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" Nucl. Acids Res. 13(12):4431-4443 (1985)
5/19/00	* 91	Chamow et al., "A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+ Effectors to Kill HIV-1-Infected Cells" Journal of Immunology 153:4268-4280 (1994)
cw	* 92	Chang et al., "Phenotypic Expression in E. coli of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" Nature 275:617-624 (October 19, 1978)
	* 93	Chaudhary et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF-κB Pathway" Immunity 7:821-830 (1997)
	* 94	Chinnaiyan and Dixit, "The Cell-Death Machine" Current Biology 6:555-562 (1996)
	* 95	Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" Cell 81:505-512 (1995)
	* 96	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" Journal of Biological Chemistry 271:4961-4965 (1996)
	* 97	Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" Science 275:1122-1126 (1997)
	* 98	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" Science 274:990-992 (1996)
	* 99	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" Journal Mol. Biol. 105:1-14 (1976)
	*100	Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" J. Mol. Biol. 196(4):901-917 (1987)
cw	*101	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" Cell 81:479-482 (1995)

Examiner: Chris Mohr — Date Considered: 9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	*102	Cohen, "Programmed Cell Death in the Immune System" Advances in Immunol. 50:55-85 (1991)
	*103	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" Monoclonal Antibodies and Cancer Therapy, Reisfeld et al., New York:Alan R. Liss, Inc. pps. 77-96 (1985)
	*104	Creighton,, "Protein Biosynthesis" Proteins: Structures and Molecular Principles San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)
	*105	Darzynkiewicz et al., "Assays of Cell Viability: Discrimination of Cells Dying by Apoptosis" Methods in Cell Biol. 41:15-38 (1994)
	*106	David et al., "Protein Iodination with Solid State Lactoperoxidase" Biochemistry 13(5):1014-1021 (1974)
	*107	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon-γ" European Journal of Immunology 17:689-693 (1987)
	*108	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" Proc. Natl. Acad. Sci. USA 80:21-25 (1983)
	*109	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" Journal of Experimental Medicine 186(7):1165-1170 (Oct 6, 1997)
	*110	Depicker et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence" J. Mol. Appl. Gen. 1:561-573 (1982)
	*111	Dieffenbach et al., PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press pps. 1-16;133-142 (1995)
	*112	Dolby et al., "Cloning and partial nucleotide sequence of human immunoglobulin μ chain cDNA from B cells and mouse-human hybridomas" Proc. Natl. Acad. Sci. USA 77(10):6027-6031 (1980)
	*113	Duksin et al., "Relationship of the Structure and Biological Activity of the Natural Homologues of Tunicamycin" Journal of Biological Chemistry 257:3105-3109 (1982)
	*114	Eck and Sprang, "The structure of tumor necrosis factor-α at 2.6 A resolution" Journal of Biological Chemistry 264(29):17595-17604 (1989)
	*115	Eck et al., "The Structure of Human Lymphotoxin (Tumor Necrosis Factor-β) at 1.9-A Resolution" J. Bio. Chem. 267:2119-2122 (1992)
	*116	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" Analytical Biochemistry 118:131-137 (1981)
	*117	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" Nature 375:78-81 (1995)
	*118	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" Molecular & Cellular Biology 5:3610-3616 (1985)
	*119	Fadok et al., "Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages" J. Immunol. 148:2207-2216 (1992)
	*120	Falkner and Zachau, "Expression of mouse immunoglobulin genes in monkey cells" Nature 298:286-288 (1982)
	*121	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from Saccharomyces cerevisiae by Use of an Epitope Addition Method" Molecular & Cellular Biology 8:2159-2165 (1988)

Examiner	Date Considered
	9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ar	*122	Fiers et al., "Complete Nucleotide Sequence of SV40 DNA" Nature 273:113-120 (May 11, 1978)
	*123	Fleer et al., "Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by Kluyveromyces Yeasts" Bio/Technology 9:968-975 (1991)
	*124	Fraser and Evan, "A License to Kill" Cell 85:781-784 (1996)
	*125	Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" Human Genet. 98:141-144 (1996)
	*126	Gething et al., "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" Nature 293:620-625 (October 22, 1981)
	127	Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells" Proc. Natl. Acad. Sci. USA 94(14):7509-7514 (Jul 8, 1997)
	*128	Goding, "Production of Monoclonal Antibodies" Monoclonal Antibodies: Principles and Practice, Academic Press, pps. 59-103 (1986)
	*129	Goeddel et al., "Direct Expression in Escherichia coli of a DNA Sequence Coding for Human Growth Hormone" Nature 281:544-548 (October 18, 1979)
	*130	Goeddel et al., "Synthesis of Human Fibroblast Interferon by E. coli" Nucleic Acids Research 8(18):4057-4074 (1980)
	*131	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" Molecular & Cellular Biology 11:3020-3026 (1991)
	*132	Gorman et al., "The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-Mediated Transfection" Proc. Natl. Acad. Sci. USA 79:6777-6781 (November 1982)
	*133	Gough et al., "Molecular cloning of seven mouse immunoglobulin κ chain messenger ribonucleic acids" Biochemistry 19:2702-2710 (1980)
	*134	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" J. Gen. Virol. 36:59-72 (1977)
	*135	Graham et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" Virology 52:456-467 (1973)
	*136	Gray et al., "Expression of Human Immune Interferon cDNA in E. coli and Monkey Cells" Nature 295:503-508 (February 11, 1982)
	*137	Greenaway et al., "Human Cytomegalovirus DNA: BamHI, EcoRI and PstI Restriction Endonuclease Cleavage Maps" Gene 18:355-360 (1982)
	*138	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" Blood 85:3378-3404 (1995)
	*139	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" J. Cell. Biochem. (abstract only Supplement 15F; P 424) pps. 113 (1991)
	*140	Hess et al., "Cooperation of Glycolytic Enzymes" Advances in Enzyme Regulation, George Weber, New York:Pergamon Press Vol. 7:149-167 (1968)
cr	*141	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" Journal of Biological Chemistry 255(24):12073-12080 (December 25, 1980)

RECEIVED
AUG 5 1998
GROUP 1600

Examiner	Date Considered
Clair M. Kaf	9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

OIPE AUG 03 1998 PATENT & TRADEMARK OFFICE

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

RECEIVED AUG 5 1998 GROUP 1800

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

aw	*142	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFα)" Journal of Biological Chemistry 264(25):14927-14934 (1989)
	*143	Holland et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" Biochemistry 17(23):4900-4907 (1978)
	*144	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V_H gene segments rearranged in vitro" J. Mol. Biol. 227:381-388 (1992)
	*145	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" Bio/Technology 6:1204-1210 (1988)
	*146	Hsiao et al., "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" Proc. Natl. Acad. Sci. USA 76:3829-3833 (1979)
	*147	Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" Cell 84:299-308 (1996)
	*148	Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" Nature 194:495-496 (1962)
	149	Iliades et al., "Triabodies: single chain Fv fragments without a linker form trivalent trimers" FEBS Letters 409(3):437-441 (Jun 16, 1997)
	*150	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" Cell 66:233-243 (1991)
	*151	Jakobovits et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-cell Development and Antibody Production" Proc. Natl. Acad. Sci. USA 90:2551-2555 (March 1993)
	*152	Jakobovits et al., "Germ-line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome" Nature 362:255-258 (March 18, 1993)
	*153	Johnson et al., "Expression and Structure of the Human NGF Receptor" Cell 47:545-554 (November 21, 1986)
	*154	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" Nature 321:522-525 (May 29, 1986)
	*155	Jones, E., "Proteinase Mutants of Saccharomyces Cerevisiae" Genetics 85(1):23-33 (1977)
	*156	Keown et al., "Methods for Introducing DNA into Mammalian Cells" Methods in Enzymology 185:527-537 (1990)
	*157	Kingsman et al., "Replication in Saccharomyces Cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast trp1 Region" Gene 7:141-152 (1979)
	*158	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" Nature 384:372-375 (1996)
	*159	Kohler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" Nature 256:495-497 (August 7, 1975)
aw	*160	Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" Proc. Natl. Acad. Sci. USA 87:8331-8335 (1990)
5/10/00	*161	Koopman et al., "Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis" Blood 84:1415-1420 (1994)

Examiner: Claire M. Kaufman — Date Considered: 9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CM	162	Kortt et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer" Protein Engineering 10(4):423-433 (Apr 1997)
	*163	Kozak, "An analysis of vertebrate mRNA sequences: intimations of translational control" Journal of Cell Biology 115:887-903 (1991)
	*164	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" The Journal of Immunology 133(6):3001-3005 (1984)
CM	*165	Krammer et al., "Regulation of Apoptosis in the Immune System" Curr. Op. Immunol. 6:279-289 (1994)
5/10/00	*166	Kyriakis et al, "Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation" Journal of Biological Chemistry 271:24313-24316 (1996)
CM	*167	Laimins et al., "Osmotic Control of kdp Operon Expression in Escherichia Coli" Proc. Natl. Acad. Sci. USA 78(1):464-468 (Jan 1981)
	*168	Lesslauer et al., "Bioactivity of recombinant human TNF receptor fragments" J. Cell. Biochem. (abstract only, Supplement 15F; P432) p. 115 (1991)
	*169	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" Proc. Natl. Acad. Sci. USA 88:2830-2834 (1991)
	*170	Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" Cell 69:915-926 (1992)
	*171	LIFESEQ Database EST Sequence Reference "1"
CM	*172	LIFESEQ Database EST Sequence Reference "2"
5/10/00	*173	Liu et al., "Dissection of TNF Receptor 1 Effector Functions: JNK Activation is not Linked to Apoptosis While NF-κB Activation Prevents Cell Death" Cell 87:565-576 (1996)
CM	*174	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" Cell 61:351-359 (April 20, 1990)
	*175	Luckow et al., "Trends in the Development of Baculovirus Expression Vectors" Bio/Technology 6:47-55 (1988)
	*176	Lusky et al., "Bovine Papilloma Virus Contains an Activator of Gene Expression at the Distal End of the Early Transcription Unit" Molecular & Cellular Biology 3(6):1108-1122 (June 1983)
	*177	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" Proc. Natl. Acad. Sci. USA 87:6393-6397 (1990)
	*178	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" Journal of Biological Chemistry 272(41):25417-25420 (Oct 10, 1997)
	*179	MacKay et al., "Differential Responses of Fibroblasts from Wild-Type and TNF-R55-Deficient Mice to Mouse and Human TNF-α Activation" J. Immunol. 153:5274-5284 (1994)
	*180	Maeda et al., "Production of Human α-interferon in Silkworm Using a Baculovirus Vector" Nature 315:592-594 (June 13, 1985)
CM	*181	Mage et al., "Preparation of Fab and F(ab')$_2$ Fragments from Monoclonal Antibodies" Monoclonal Antibody Production Techniques and Applications, New York:Marcel Dekker, Inc. pps. 79-97 (1987)

Examiner	Date Considered
Claire M. Kaplan	9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant	
Ashkenazi et al.	
Filing Date	**Group**
09 Feb 1998	~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	*182	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" EMBO Journal 9:1063-1068 (1990)
	*183	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" Nature 336:348-352 (1988)
	*184	Mantei et al., "Rabbit β-globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit β-globin Chromosomal DNA" Nature 281:40-46 (September 6, 1979)
	*185	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" J. Mol. Biol. 222:581-597 (1991)
	*186	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" Current Biology 6(6):750-752 (1996)
	*187	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF-κB" Curr. Biol. 6(12):1669-1676 (1996)
	*188	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF-κB and AP-1" Journal of Biological Chemistry 272(22):14029-14032 (1997)
	*189	Marsters et al., "Interferon γ Signals Via a High-Affinity Multisubunit Receptor Complex That Contains Two Types of Polypeptide Chain" Proc. Natl. Acad. Sci. USA 92:5401-5405 (1995)
	190	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" Current Biology 7:1003-1006 (1997)
	*191	Martin et al., "Cell-free Reconstitution of Fas-, UV Radiation- and Ceramide-induced Apoptosis" EMBO Journal 14(21):5191-5200 (1995)
	*192	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K^+ Channel Currents" Science 255:192-194 (1992)
	*193	Mather et al., "Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium" Annals N.Y. Acad. Sci. 383:44-68 (1982)
	*194	Mather et al., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" Biol. Reprod. 23:243-252 (1980)
	*195	Maxam et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages" Methods in Enzymology 65:499-560 (1980)
	*196	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" Nature 348:552-554 (1990)
	*197	Messing et al., "A System for Shotgun DNA Sequencing" Nucleic Acids Research 9(2):309-321 (1981)
	*198	Miller et al., "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes" Genetic Engineering, Setlow et al., Plenum Publishing Vol. 8:277-298 (1986)
	*199	Milstein et al., "Hybrid Hybridomas and Their Use in Immunohistochemistry" Nature 305:537-540 (1983)
	*200	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" Cell 87(3):427-436 (1996)
	*201	Moore et al., "Apoptosis in CHO Cell Batch Cultures: Examination by Flow Cytometry" Cytotechnology 17:1-11 (1995)

Examiner	Date Considered
Claire M. Kosz	9/28/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

AUG 0 3 1998 PATENT & TRADEMARK OFFICE

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

RECEIVED AUG 5 1998 GROUP 1800

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

an	*202	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" Proc. Natl. Acad. Sci. USA 81:6851-6855 (November 1984)
	*203	Morrison et al., "Transfer and expression of immunoglobulin genes" Annual Review of Immunology 2:239-256 (1984)
	*204	Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" Science 229:1202-1207 (September 20, 1985)
	*205	Mulligan et al., "Expression of a Bacterial Gene in Mammalian Cells" Science 209:1422-1427 (Sep 1980)
	*206	Munro, "Uses of chimaeric antibodies" Nature 312:597 (1984)
	*207	Munson et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" Analytical Biochemistry 107:220-239 (1980)
	*208	Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" Cell 85:817-827 (1996)
	*209	Nagata, "Apoptosis by Death Factor" Cell 88:355-365 (1997)
	*210	Nagata et al., "The Fas Death Factor" Science 267:1449-1456 (1995)
	*211	NCBI/GenBank EST; Locus AA232440:(computer printout attached)
	*212	NCBI/GenBank EST; Locus HS75A7R:(computer printout attached)
	*213	NCBI/GenBank EST; Locus AA223122:(computer printout attached)
	*214	Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" Nature 312:604-608 (December 13, 1984)
	*215	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" EMBO Journal 9:3269-3278 (1990)
	*216	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" The Journal of Histochemistry and Cytochemistry 30(5):407-412 (1982)
	*217	Osborne et al., "Transcription Control Region Within the Protein-coding Portion of Adenovirus E1A Genes" Molecular & Cellular Biology 4(7):1293-1305 (July 1984)
	*218	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" Protein Eng. 3(6):547-553 (1990)
	*219	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" Journal of Immunological Methods 40:219-230 (1981)
	*220	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" Science 277:815-818 (1997)
cer	*221	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" Science 276:111-113 (1997)

Examiner	Date Considered
Claire M. Kaye	9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

au	*222	Pavlakis et al., "Expression of Two Human Growth Hormone Genes in Monkey Cells Infected by Simian Virus 40 Recombinants" Proc. Natl. Acad. Sci. USA 78(12):7398-7402 (December 1981)
	*223	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" Eur. J. Haemotol. 41:414-419 (1988)
	*224	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" Nature 312:724-729 (1984)
	*225	Peppel and Beutler, "Chimaeric TNF-Receptor-IgG Molecule Acts as Soluble Inhibitor of TNF Mediated Cytotoxicity" J. Cell. Biochem. (abstract only, Supplement 15F; P439) p. 118 (1991)
	*226	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" Journal of Biological Chemistry 271:12687-12690 (1996)
	*227	Presta et al., "Humanization of an Antibody Directed Against IgE" J. Immunol. 151(5):2623-2632 (September 1, 1993)
	*228	Presta, L., "Antibody Engineering" Curr. Op. Struct. Biol. 2:593-596 (1992)
	*229	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" Nature 325:593-597 (February 12, 1987)
	*230	Raff, "Social Controls on Cell Survival and Cell Death" Nature 356:397-400 (1992)
	*231	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds To The p55 TNF Receptor Death Domain" Euro. Cytokine Network (abstract No. 82) 7:210 (April-Jun 1996)
	*232	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds to the p55 TNF Receptor Death Domain" Programmed Cell Death Meeting (abstract only) pps. 127 (20-24 September 1995)
	*233	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1β Converting Enzyme" Cell 69:597-604 (May 15, 1992)
	*234	Reyes et al, "Expression of Human β-interferon cDNA Under the Control of a Thymidine Kinase Promoter from Herpes Simplex Virus" Nature 297:598-601 (June 17, 1982)
	*235	Rice and Baltimore, "Regulated expression of an immunoglobulin κ gene introduced into a mouse lymphoid cell line" Proc. Natl. Acad. Sci. USA 79:7862-7865 (1982)
	*236	Riechmann et al., "Reshaping Human Antibodies for Therapy" Nature 332:323-327 (March 24, 1988)
	*237	Rothe et al., "A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDA tumor necrosis factor receptor" Cell 78:681-692 (1994)
	*238	Sachs et al., "Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy" Blood 82:15-21 (1993)
	*239	Sambrook et al. Molecular Cloning: A Laboratory Manual, Second edition, New York:Cold Spring Harbor Laboratory Press (1989)
	*240	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" Cell 61:361-370 (April 20, 1990)
au	*241	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" Proc. Natl. Acad. Sci. USA 83:1881-1885 (1986)

Examiner: Claire M. Kolker

Date Considered: 9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

RECEIVED AUG 5 1998 GROUP 1800

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AW	*242	Schneider et al., "Characterization of two receptors for TRAIL" FEBS Letters 416:329-334 (1997)
	*243	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL" Current Biology 7:693-696 (1997)
	*244	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α Inhibitor" Journal of Biological Chemistry 264:11966-11973 (1989)
	*245	Sharon et al., "Expression of a V_HC_K chimaeric protein in mouse myeloma cells" Nature 309:364-367 (1984)
	*246	Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" Gene 23:315-330 (1983)
	*247	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" Science 277:818-821 (1997)
	248	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity" Journal of Immunology 148(9):2918-2922 (May 1, 1992)
	*249	Siebenlist et al., "E. Coli RNA Polymerase Interacts Homologously with Two Different Promoters" Cell 20:269-281 (June 1980)
	*250	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" Cell 89:309-319 (Apr 18, 1997)
	*251	Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" The Journal of Immunology 151(4):2296-2308 (Aug 1993)
	*252	Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" Journal of Biological Chemistry 266:14163-14166 (1991)
	*253	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" Science 248:1019-1023 (May 25, 1990)
	*254	Smith et al., "T2 Open reading frame from the shope fibroma virus encodes a soluble form of the TNF receptor" Biochem. & Biophys. Res. Comm. 176:335-342 (1991)
	*255	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death" Cell 76:959-962 (1994)
	*256	Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" Archives of Biochemistry & Biophysics 259(1):52-57 (1987)
	*257	Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter" J. Molec. Appl. Genet. 1:327-341 (1982)
	*258	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" EMBO Journal 8(5):1403-1410 (1989)
	*259	Steller, "Mechanisms and Genes of Cellular Suicide" Science 267:1445-1449 (1995)
	260	Stevenson et al., "A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge" Anti-Cancer Drug Design 3(4):219-230 (Mar 1989)
AW	*261	Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" Nature 282:39-43 (November 1, 1979)

Examiner	Date Considered
Clare M. Kapf	9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

RECEIVED
AUG 5 1998
GROUP 1800

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	*262	Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" Cell 75:1169-1178 (1993)
	*263	Sugden et al., "A Vector that Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus" Molecular & Cellular Biology 5:410-413 (1985)
	*264	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" Methods in Enzymology 121:210-228 (1986)
	*265	Suva et al., "A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression" Science 237(4817):893-896 (Aug. 1987)
	*266	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" Immunogenetics 37:199-203 (1993)
	*267	Tartaglia et al., "A novel domain within the 55kd TNF receptor signals cell death" Cell 74(5):845-853 (1993)
	*268	Tewari et al., "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product" Journal of Biological Chemistry 270:3255-3260 (1995)
	*269	Tewari et al., "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" Curr. Op. Genet. Develop. 6:39-44 (1996)
	*270	Tewari et al., "Yama/CPP32β, a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" Cell 81:801-809 (1995)
	*271	Thomas et al., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" Cell 51:503-512 (1987)
	*272	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" Proc. Natl. Acad. Sci. USA 77(9):5201-5205 (September 1980)
	*273	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" Science 267:1456-1462 (1995)
	*274	Thotakura et al., "Enzymatic Deglycosylation of Glycoproteins" Meth. Enzymol. 138:350-359 (1987)
	*275	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" EMBO Journal 10(12):3655-3659 (1991)
	*276	Traunecker et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-immunoglobulin Molecules" Nature 339:68-70 (1989)
	*277	Tschumper et al., "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" Gene 10:157-166 (1980)
	*278	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" Virology 184:370-382 (1991)
	*279	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the shope fibroma virus genome" Virology 160:20-29 (1987)
	*280	Urlaub et al., "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" Proc. Natl. Acad. Sci. USA 77(7):4216-4220 (July 1980)
	*281	Van den Berg et al., "Kluyveromyces as a Host for Heterologous Gene Expression: Expression and Secretion of Prochymosin" Bio/Technology 8:135-139 (1990)

Examiner	Date Considered
Clare M. Kapatoes	9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office

Atty Docket No.	Serial No.
P1101P1	09/020,746
Applicant: Ashkenazi et al.	
Filing Date: 09 Feb 1998	Group: ~~1642~~ 1646

LIST OF DISCLOSURES CITED BY APPLICANT
(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cw	*282	Van Solingen et al., "Fusion of Yeast Spheroplasts" J. Bact. 130:946-947 (1977)
	*283	Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" Science 239:1534-1536 (Mar 25, 1988)
	*284	Verma et al., "Rel/NF-κB/IκB Family: Intimate Tales of Association and Dissociation" Genes Develop. 9:2723-2735 (1995)
	*285	von Bulow et al., "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" Science 278:138-141 (Oct 3, 1997)
	*286	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" EMBO Journal 16(17):5386-5397 (1997)
	*287	Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis" Nature 356:314-317 (1992)
	*288	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" Proc. Natl. Acad. Sci. USA 88:159-163 (1991)
	*289	Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" Gene 34(2-3):315-323 (1985)
	*290	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" Philos. Trans. R. Soc. London Ser A 317:415-423 (1986)
	*291	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" Immunity 3:673-682 (1995)
	292	Wolff et al., "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice" Cancer Research 53(11):2560-2565 (Jun 1, 1993)
	*293	Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells" Journal of Biological Chemistry 272(40):25190-25194 (Oct 3, 1997)
	*294	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene" Nature Genetics 17:141-143 (October 1997)
	*295	Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" Journal of Biological Chemistry 266:12099-12104 (1991)
	*296	Yaniv, M., "Enhancing Elements for Activation of Eukaryotic Promoters" Nature 297(6):17-18 (May 1982)
	*297	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" Journal of Experimental Medicine 169:1747-1756 (1989)
	*298	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" Nature 377:348-351 (1995)
	*299	Zola, "Using Monoclonal Antibodies: Soluble Antigens" Monoclonal Antibodies: A Manual of Techniques, CRC Press, Chapter 6, pps. 147-158 (1987)
cw	*300	Zoller et al., "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" Nucl. Acids Res. 10(20):6487-6500 (1982)

Examiner: Claire M. Kolker Date Considered: 9/23/99

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.